Italy Fusion Biopsy Market Size & Outlook, 2024-2030

The fusion biopsy market in Italy is expected to reach a projected revenue of US$ 34.8 million by 2030. A compound annual growth rate of 8.3% is expected of Italy fusion biopsy market from 2025 to 2030.
Revenue, 2024 (US$M)
$21.6
Forecast, 2030 (US$M)
$34.8
CAGR, 2025 - 2030
8.3%
Report Coverage
Italy

Italy fusion biopsy market highlights

  • The Italy fusion biopsy market generated a revenue of USD 21.6 million in 2024 and is expected to reach USD 34.8 million by 2030.
  • The Italy market is expected to grow at a CAGR of 8.2% from 2025 to 2030.
  • In terms of segment, transrectal was the largest revenue generating biopsy route in 2024.
  • Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.

Fusion biopsy market data book summary

Market revenue in 2024USD 21.6 million
Market revenue in 2030USD 34.8 million
Growth rate8.2% (CAGR from 2024 to 2030)
Largest segmentTransrectal
Fastest growing segmentTransperineal
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTransrectal, Transperineal
Key market players worldwideKoninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care

Other key industry trends

  • In terms of revenue, Italy accounted for 2.9% of the global fusion biopsy market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany fusion biopsy market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 45.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Fusion Biopsy Market Companies

Name Profile # Employees HQ Website

Italy fusion biopsy market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.


Transrectal was the largest segment with a revenue share of 87.5% in 2024. Horizon Databook has segmented the Italy fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.


Italy's fusion biopsy market was valued at USD 14.9 million and is expected to exhibit a CAGR of 11.2% during the forecast period. Key drivers anticipated to propel the market are the increasing incidence of prostate cancer and the growing geriatric population.

In Italy, the incidence of prostate cancer is increasing, while the survival rate is falling. According to Prostate Cancer Prevention, the incidence of prostate cancer in Italy is approximately 12%, surpassing lung cancer at 10%.

The growing incidence of prostate cancer in Italy is primarily due to preexisting illnesses. The abovementioned factors are expected to boost the demand for fusion biopsy in Italy during the forecast period.

Reasons to subscribe to Italy fusion biopsy market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Italy fusion biopsy market databook

  • Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Italy fusion biopsy market , including forecasts for subscribers. This country databook contains high-level insights into Italy fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Italy fusion biopsy market size, by biopsy route, 2018-2030 (US$M)

Italy Fusion Biopsy Market Outlook Share, 2024 & 2030 (US$M)

Italy fusion biopsy market size, by biopsy route, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more